David Lebovitz
Stock Analyst at Citigroup
(3.10)
# 1,254
Out of 4,734 analysts
91
Total ratings
62.9%
Success rate
6.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $38.76 | +90.92% | 2 | Nov 14, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $93 → $81 | $62.53 | +29.54% | 2 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $382 → $371 | $307.08 | +20.82% | 3 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $291 → $342 | $264.99 | +29.06% | 30 | Aug 2, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $47.98 | -20.80% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $45.25 | -62.43% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $111.96 | -17.83% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $57.52 | -6.12% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $32.68 | +7.10% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $3.00 | +466.67% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $3.79 | +190.24% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $131.06 | +51.84% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $34 → $32 | $0.69 | +4,558.61% | 2 | Nov 3, 2020 |
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $38.76
Upside: +90.92%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Neutral
Price Target: $93 → $81
Current: $62.53
Upside: +29.54%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $382 → $371
Current: $307.08
Upside: +20.82%
Alnylam Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $291 → $342
Current: $264.99
Upside: +29.06%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $47.98
Upside: -20.80%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $45.25
Upside: -62.43%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $111.96
Upside: -17.83%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $57.52
Upside: -6.12%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $32.68
Upside: +7.10%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $3.00
Upside: +466.67%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $3.79
Upside: +190.24%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $131.06
Upside: +51.84%
Nov 3, 2020
Maintains: Overweight
Price Target: $34 → $32
Current: $0.69
Upside: +4,558.61%